Cutler Group LP Verastem, Inc. Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 14, 2022	SELL	$1.06 - $2.1 $212 - $420	-200 Reduced 28.57%	500 $0
Q4 2021 Jan 18, 2022	SELL	$2.05 - $3.2 $615 - $960	-300 Reduced 30.0%	700 $1,000
Q3 2021 Oct 26, 2021	SELL	$2.54 - $4.07 $4,064 - $6,512	-1,600 Reduced 61.54%	1,000 $3,000
Q2 2021 Jul 19, 2021	BUY	$2.57 - $4.85 $5,397 - $10,185	2,100 Added 420.0%	2,600 $10,000
Q1 2020 May 07, 2020	SELL	$1.26 - $3.38 $1,386 - $3,718	-1,100 Reduced 68.75%	500 $1,000
Q1 2019 May 10, 2019	SELL	$2.79 - $4.09 $1,953 - $2,863	-700 Reduced 30.43%	1,600 $4,000
Q4 2018 Feb 05, 2019	BUY	$3.23 - $7.01 $2,584 - $5,608	800 Added 53.33%	2,300 $7,000
Q3 2018 Nov 07, 2018	BUY	$6.86 - $9.97 $9,604 - $13,958	1,400 Added 1400.0%	1,500 $10,000
Q4 2017 Jan 17, 2018	BUY	$2.99 - $4.85 $299 - $484	100	100 $0

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.29B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.